scholarly journals Treatment of Allergic Rhinitis: Anticholinergics, Glucocorticotherapy, Leukotriene Antagonists, Omalizumab and Specific-Allergen Immunotherapy

10.5772/48800 ◽  
2012 ◽  
Author(s):  
Jesus Jurado-Palomo ◽  
Irina Diana ◽  
Maria Teresa Belver Gonzalez ◽  
Alvaro Moreno-Ancillo ◽  
Ana Carmen Gil Adrados ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Allergen Immunotherapy ◽  
Leukotriene Antagonists ◽  
Specific Allergen

scholarly journals Treatment strategy of allergic rhinitis in the face of modern world threats

2018 ◽  
Vol 72 (2) ◽  
pp. 1-12 ◽  
Author(s):  
Piotr Rapiejko ◽  
Dariusz Jurkiewicz ◽  
Wioletta Pietruszewska ◽  
Beata Zielnik-Jurkiewicz ◽  
Jarosław Woroń ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Allergen Immunotherapy ◽  
Modern World ◽  
Proper Treatment ◽  
Treatment Persistence ◽  
Factors Affecting ◽  
The Face ◽  
Selection Of ◽  
Specific Allergen

Allergic rhinitis (AR) is the most common form of allergy, which - as epidemiological research has shown - applies to nearly 25% of the population. AR significantly affects the quality of life of the patient, and the more severe the disease, the greater the risk of developing bronchial asthma. One of the factors affecting the severity of symptoms and the degree of their control is air pollution. In some patients, despite proper treatment, persistence or only partial remission of symptoms (uncontrolled allergic rhinitis) is observed. This can lead to an increase in comorbidities - inflammation of the paranasal sinuses, otitis media and asthma - both in children and in adults. The treatment of allergic rhinitis, in accordance with the standards, consists in: education of the patient, elimination of the allergen from the environment and factors intensifying the course of the disease, selection of proper pharmacotherapy and specific allergen immunotherapy. Many factors influence the selection of the antihistamine used, e.g., the opportunity of safe increase of the dosage.

Specific allergen immunotherapy: effect on IgE, IgG4 and chemokines in patients with allergic rhinitis

2016 ◽  
Vol 76 (2) ◽  
pp. 118-127 ◽  
Author(s):  
Eva Stylianou ◽  
Thor Ueland ◽  
Fredrik Borchsenius ◽  
Annika E. Michelsen ◽  
Reidun Øvstebø ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Allergen Immunotherapy ◽  
Specific Allergen

scholarly journals Quality of life of patients undergoing specific allergen immunotherapy in allergic rhinitis

2020 ◽  
Vol 27 (4) ◽  
pp. 657-663
Author(s):  
Magdalena Brodowicz-Król ◽  
Ewa Guz ◽  
Dorota Hawryluk ◽  
Ewa Kulbaka ◽  
Lech Panasiuk ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Allergic Rhinitis ◽  
Allergen Immunotherapy ◽  
Specific Allergen

Serum immunoglobulin E reactivity to cross-reacting panallergen components in north-eastern Poland patients pollen sensitized

2020 ◽  
Vol 41 (3) ◽  
pp. 183-191
Author(s):  
Krzysztof Kowal ◽  
Agnieszka Pampuch ◽  
Ewa Sacharzewska ◽  
Ewa Swiebocka ◽  
Zenon Siergiejko ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Allergen Immunotherapy ◽  
Immunoglobulin E ◽  
Pollen Allergy ◽  
Serum Ige ◽  
Ige Reactivity ◽  
Allergen Components ◽  
North Eastern ◽  
Allergen Sources ◽  
Seasonal Pollen

Background: The presence of immunoglobulin E (IgE), which cross-reacts with allergen components, such as profilins, polcalcins, and cross-reacting carbohydrate determinants (CCD), creates a problem when selecting patients for allergen immunotherapy by using conventional methods. The aim of this study was to evaluate the prevalence of sensitization to profilins, polcalcins, and CCDs in patients with seasonal pollen allergic rhinitis. Methods: The study was performed on a group of 112 patients with seasonal pollen allergic rhinitis, ages 14 to 55 years, with sensitization to at least one seasonal allergen (IgE > 0.7 kUA/L). The presence of IgE sensitization to recombinant (r) Bet v 2, rPhl p 12, rBet v 4, rPhl p 7, and CCDs, in addition to rBet v 1, rPhl p 1, rPhl p 5, was evaluated by using a multiparameter immunoblot. Results: Among the studied patients, 64.3, 80.4, and 41.1% were sensitized to birch, timothy grass, and mugwort pollen, respectively. Sensitization to profilins rBet v 2/Phl p 12 was demonstrated in 28.6%, to polcalcins Bet v 4/Phl p 7 in 8.9%, and to CCDs in 25%. In 29.3%, serum IgE reactivity to any of the cross-reactive components could be demonstrated. Serum IgE reactivity to rBet v 2 was always accompanied by IgE reactivity to rPhl p 12, and IgE reactivity to rBet v 4 was always accompanied by IgE reactivity to rPhl p 7. Among the patients with pollinosis co-sensitized to at least two allergen sources according to extract-based diagnosis, possible false-positive results due to sensitization to cross-reactive components were detected in 17.9%. Conclusion: Evaluation of sensitization to cross-reacting components may be useful in evaluation of patients with pollen allergy who are being assessed for allergen immunotherapy to optimize the constitution of their immunotherapy vaccines.

scholarly journals @IT2020: An innovative algorithm for allergen immunotherapy prescription in seasonal allergic rhinitis

2021 ◽  
Author(s):  
Stefania Arasi ◽  
Sveva Castelli ◽  
Marco Di Fraia ◽  
Danilo Villalta ◽  
Salvatore Tripodi ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Seasonal Allergic Rhinitis ◽  
Allergen Immunotherapy
Sign in / Sign up

Export Citation Format

Share Document